Adding the tyrosine kinase inhibitor to a subset of MPAL patients who have BCR-ABL fusion has been demonstrated to improve the outcome with acceptable toxicities and is currently the standard of care (23). Here, BCR is linked to mixed phenotype acute leukemia.